`RESEARCH
`
`
`
`APPLICATION NUMBER:
`
`213801Orig1s000
`
`OFFICER/EMPLOYEE LIST
`
`
`
`
`
`MEMORANDUM
`
`DATE:
`
`March 26, 2021
`
`DEPARTMENT OF HEALTH AND HUMAN SERVICES
`PUBLIC HEALTH SERVICE
`FOOD AND DRUG ADMINISTRATION
`CENTER FOR DRUG EVALUATION AND RESEARCH
`
`TO:
`
`FROM:
`
`Administrative file for NDA 213801
`
`Nenita Crisostomo, Regulatory Health Project Manager
`Division of Urology, Obstetrics and Gynecology, Office of Regulatory Operations
`
`SUBJECT: Officer/Employee List for NDA 213801
`
`APPLICATION/DRUG:
`
`NDA 213801, Myrbetriq Granules(mirabegron for extended-oral
`suspension), 8mg/mL
`
`The following officers or employees of FDA participated in the decision to approve this
`application and consented to be identified on this list:
`
`Alexander, John
`Bain, Sam
`Baugh, Denise
`Boley, Elena
`Booker, Nyedra
`Burnett, Marquita
`Cai, Hong
`Crisostomo, Nenita
`Fashina, Oyinlola
`God, Jason
`Guity, Niquiche
`Guo, Jia
`Hatfield, Kimberly
`Hirsch, Mark
`Johnson, Aisha
`Khurana, Mona
`Kolhatkar, Vidula
`Lin, Daphne TY
`Lu, Min
`Lu, Yanhui
`McLeod-Flynn, Laurie
`Nemecek, Julie
`Nguyen, Christine
`Noory, Assadollah
`Roule, Jeannie
`Tuchman, Shamir
`
`Reference ID: 4772718
`
`
`
`Varghese, Elvy
`Wang, Yun
`Williams, Marcia Britt
`Wilson, Wendy
`Yu, Jingyu (Jerry)
`Zou, Peng
`
`Reference ID: 4772718
`
`(
`
`
`
`